Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503141 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL17722938 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL19046498 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL20467806 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL19708237 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL25009079 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL24477218 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL17815262 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL21780990 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL19709072 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200199242-A1 | CONSTRUCT-PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | ORBIMED ADVISORS LLC | 2020-06-25 | — | — | US | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170298139-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016094505-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094509-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094517-A1 | BCL-XL INHIBITORY COMPOUNDS AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | SIRT2 942/4885SIRT1 871/4885SIRT5 1123/4885 |
| US-20170298139-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | SIRT2 4743/4885SIRT1 4682/4885SIRT5 4022/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | SIRT2 973/4885SIRT1 1185/4885SIRT5 1519/4885 |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | SIRT2 1129/4885SIRT1 1553/4885SIRT5 538/4885 |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | SIRT2 1593/4885SIRT1 1444/4885SIRT5 1462/4885 |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | SIRT2 942/4885SIRT1 871/4885SIRT5 1123/4885 |
| US-20200199242-A1 | CONSTRUCT-PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | NGLY1, MICA, VIP | SIRT2 4707/4885SIRT1 4554/4885SIRT5 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.